Syngoi Technologies, S.L.

Syngoi Technologies develops optimized linear synthetic DNA to support biotechnology, pharmaceuticals, and genetic research, enhancing precision in DNA synthesis for various applications. Syngoi Technologies, founded in 2021 in Spain, specializes in producing optimized synthetic DNA. The founder has not been previously associated with other companies, and no significant pivots in business strategy have been noted. Syngoi specializes in the production of optimized linear synthetic DNA, catering primarily to sectors such as biotechnology, pharmaceuticals, and genetic research.

Their core offerings support a wide array of applications, including gene editing, synthetic biology, and biopharmaceutical development. These products enhance the precision and efficiency of DNA synthesis, addressing challenges in genetic sequencing and manipulation. Syngoi’s clientele includes academic institutions, research organizations, and biotech firms across North America and Europe, where the demand for high-quality synthetic DNA is growing. By focusing on these markets, Syngoi aims to facilitate advancements in personalized medicine and genetic research.

Syngoi generates revenue through a B2B model, primarily engaging with research institutions and biotechnology companies that require tailored synthetic DNA solutions for their projects. Transactions typically involve direct sales agreements based on specific research needs. The pricing structure accommodates both small-scale research projects and large-scale commercial applications, with flagship products including proprietary DNA constructs optimized for various applications in genetic manipulation and analysis. Through these targeted offerings, Syngoi positions itself within the synthetic biology market, fostering long-term partnerships with its customers.

IIn January 2026, Artis BioSolutions, a portfolio company of Oak HC/FT, agreed to acquire Syngoi Technologies, S. L. from Buenavista Equity Partners. Financial terms were not disclosed.

This transaction will enable Syngoi to expand its capabilities and enhance its position in developing advanced therapies. The company plans to launch new products aimed at advancing genetic research, with specific release dates to be determined.